CHEK2 and cancer: From a hereditary standpoint, pathogenic CHEK2 variants—well established in other cancers like breast—appear to confer at most a low-to-moderate increase in RCC risk: associations (including with I157T and c.1100delC) have been reported but are inconsistent and show limited penetrance [74].